Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18401918 | POLYELECTROCHROMISM OF ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENE-BRIDGED TWO Ru(CO)Cl(PiPr3)2 ENTITIES | January 2024 | March 2024 | Allow | 2 | 0 | 0 | No | No |
| 18384982 | 4,4'-NAPHTHALENE-1,5-DIYLBIS(DIAZENE-2,1-DIYL)BIS(2-METHYLPHENOL)AS AN ANTIOXIDANT COMPOUND | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18383754 | 4-((5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)METHYL)BENZOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 2 | 0 | No | No |
| 18222277 | SPIROOXINDOLE-COPPER COMPLEX AS NOVEL EFFICIENT ANTICORROSION AGENT FOR C-STEEL | July 2023 | September 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18212483 | CHARGE TRANSPORTATION IN NANOSTRUCTURED FUNCTIONAL SELENIUM-CONTAINING LIQUID CRYSTALLINE MATERIALS | June 2023 | September 2023 | Allow | 3 | 0 | 0 | No | No |
| 18252821 | COMPOUND AND METHOD FOR PRODUCING SAME | May 2023 | October 2023 | Allow | 6 | 0 | 0 | No | No |
| 18178176 | 4-SUBSTITUED CYTISINE ANALOGUES | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18162301 | ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES | January 2023 | June 2023 | Allow | 4 | 1 | 0 | No | No |
| 18095051 | SILYL PHOSPHINE COMPOUND, PROCESS FOR PRODUCING SILYL PHOSPHINE COMPOUND AND PROCESS FOR PRODUCING InP QUANTUM DOTS | January 2023 | May 2024 | Abandon | 16 | 2 | 0 | Yes | No |
| 18080861 | PALLADIUM PRECATALYST FOR CROSS-COUPLING REACTION AND SYNTHESIS METHOD THEREOF | December 2022 | January 2024 | Allow | 13 | 2 | 0 | No | No |
| 17983474 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | November 2022 | October 2023 | Allow | 11 | 1 | 0 | No | No |
| 17983501 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | November 2022 | October 2023 | Allow | 11 | 1 | 0 | No | No |
| 17974258 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | October 2022 | August 2023 | Allow | 10 | 1 | 0 | No | No |
| 17944783 | BINUCLEAR IRON-FUSED PORPHYRIN | September 2022 | July 2023 | Allow | 10 | 1 | 0 | No | No |
| 17931843 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | September 2022 | January 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 17885475 | JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE | August 2022 | June 2023 | Allow | 10 | 1 | 0 | No | No |
| 17860873 | MULTIFUNCTIONAL CONJUGATES | July 2022 | December 2023 | Allow | 18 | 2 | 0 | No | No |
| 17788901 | METHOD OF STABILIZING PERFLUORODIOXOLANE COMPOUND, PERFLUORODIOXOLANE COMPOUND-CONTAINING COMPOSITION AND METHOD OF PRODUCING PERFLUORODIOXOLANE COMPOUND POLYMER | June 2022 | May 2023 | Allow | 11 | 0 | 0 | No | No |
| 17835213 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | June 2022 | February 2023 | Allow | 9 | 0 | 0 | No | No |
| 17752201 | METHOD OF THE ISOLATING CHLOROSESAMONE OR CHLOROSESAMONE-CONTAINING FRACTION FROM ROOTS OF GENUS SESAMUM, AND APPLICATION OF THE FRACTION THEREOF | May 2022 | May 2024 | Abandon | 23 | 2 | 0 | No | No |
| 17743205 | Menaquinol Compositions and Methods of Treatment | May 2022 | January 2023 | Allow | 9 | 0 | 0 | No | No |
| 17733766 | Nanoprobe-Metal Chelator Complexes | April 2022 | February 2023 | Allow | 9 | 0 | 0 | No | No |
| 17728514 | METHOD OF FIXATING CARBON DIOXIDE TO SUBSTITUTED OXAZOLIDINONES | April 2022 | June 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17723313 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | April 2022 | November 2023 | Allow | 19 | 2 | 0 | No | No |
| 17718728 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | April 2022 | August 2023 | Abandon | 16 | 0 | 1 | No | No |
| 17706283 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | March 2022 | April 2023 | Allow | 13 | 1 | 0 | No | No |
| 17700500 | 7,7'-DIHALO-3,3,3',3'-TETRAMETHYL-1,1'-SPIROBIINDANE AND PREPARATION METHOD THEREOF | March 2022 | November 2023 | Allow | 19 | 1 | 0 | No | No |
| 17696125 | BISPHOSPHITE LIGANDS BASED ON BENZOPINACOL AND 1,3-PROPANEDIOL | March 2022 | September 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17654722 | CXCR4 INHIBITORS AND USES THEREOF | March 2022 | May 2023 | Allow | 14 | 1 | 0 | No | No |
| 17688001 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | March 2022 | March 2023 | Allow | 12 | 1 | 0 | No | No |
| 17636717 | CORROLE-BASED FRAMEWORKS AND METHODS OF USE THEREOF | February 2022 | January 2023 | Allow | 11 | 1 | 0 | No | No |
| 17634480 | DIVALENT METAL ASCORBATE GLYCINATE CO-SALT | February 2022 | August 2022 | Allow | 6 | 0 | 0 | Yes | No |
| 17584362 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | January 2022 | March 2023 | Allow | 14 | 2 | 0 | Yes | No |
| 17583159 | CHIRAL N-HETEROCYCLIC PHOSPHORODIAMIDIC ACIDS (NHPAS) AND DERIVATIVES AS NOVEL BRONSTED ACID CATALYSTS | January 2022 | September 2023 | Allow | 19 | 1 | 1 | No | No |
| 17570502 | SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT | January 2022 | May 2023 | Allow | 16 | 1 | 0 | No | No |
| 17647232 | ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES | January 2022 | April 2022 | Allow | 3 | 1 | 0 | Yes | No |
| 17620233 | OPTICALLY ACTIVE BISPHOSPHINOMETHANE, METHOD FOR PRODUCING THE SAME, AND TRANSITION METAL COMPLEX AND ASYMMETRIC CATALYST | December 2021 | September 2022 | Allow | 9 | 1 | 0 | Yes | No |
| 17548899 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | December 2021 | March 2023 | Allow | 15 | 2 | 0 | No | No |
| 17618110 | Method for Fluoroalkylation of Enamines | December 2021 | April 2023 | Allow | 16 | 2 | 1 | No | No |
| 17543479 | RETINOID DERIVATIVES WITH ANTITUMOR ACTIVITY | December 2021 | July 2023 | Allow | 19 | 1 | 1 | No | No |
| 17542908 | TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | December 2021 | October 2022 | Allow | 10 | 0 | 0 | No | No |
| 17540601 | PROCESS FOR THE CARBONYLATION OF EPOXIDES | December 2021 | December 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17523880 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | November 2021 | January 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17517846 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | November 2021 | November 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17515910 | REACTIONS OF OLEFIN DERIVATIVES IN THE PRESENCE OF METHATHESIS CATALYSTS | November 2021 | December 2023 | Allow | 25 | 1 | 0 | Yes | No |
| 17507004 | SELECTIVE ALKYLATION OF CYCLOPENTADIENE | October 2021 | March 2023 | Allow | 16 | 0 | 0 | No | No |
| 17600251 | PRODUCTION METHOD OF BIARYLPHOSPHINE | September 2021 | August 2022 | Allow | 10 | 0 | 0 | No | No |
| 17476353 | METHODS FOR TREATING PTEN-MUTANT TUMORS | September 2021 | June 2023 | Abandon | 21 | 1 | 1 | No | No |
| 17470980 | FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR | September 2021 | January 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17436917 | INTEGRATED METHODS AND SYSTEMS FOR PRODUCING AMIDE AND NITRILE COMPOUNDS | September 2021 | July 2022 | Allow | 10 | 2 | 0 | Yes | No |
| 17459550 | POLYCYCLIC AROMATIC COMPOUND AND LIGHT EMISSION LAYER-FORMING COMPOSITION | August 2021 | June 2023 | Allow | 22 | 2 | 0 | No | No |
| 17407951 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | August 2021 | January 2023 | Allow | 17 | 1 | 0 | No | No |
| 17404497 | CD73 INHIBITORS | August 2021 | September 2022 | Allow | 13 | 0 | 0 | No | No |
| 17403610 | COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED FROM A DIASTEREOISOMERICALLY ENRICHED PCTA AND PREPARATION AND PURIFICATION PROCESS | August 2021 | February 2022 | Allow | 6 | 0 | 0 | Yes | No |
| 17400421 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | August 2021 | March 2023 | Allow | 19 | 2 | 0 | No | No |
| 17399338 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | August 2021 | January 2023 | Allow | 17 | 1 | 0 | No | No |
| 17395194 | Production method of cyclic compounds by olefin metathesis reaction and use of ruthenium catalysts in production of cyclic olefines by olefin metathesis reaction | August 2021 | August 2023 | Abandon | 25 | 1 | 1 | No | No |
| 17395433 | PHENYL CYCLOHEXANONE DERIVATIVES AND METHODS OF MAKING AND USING THEM | August 2021 | July 2023 | Allow | 23 | 1 | 0 | No | No |
| 17424189 | Method for Preparation of Fluoro Alkylated 1,4-Dioxene by Homogeneous NI Catallysis | July 2021 | January 2022 | Allow | 6 | 0 | 0 | No | No |
| 17423638 | COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED FROM A DIASTEREOISOMERICALLY ENRICHED PCTA AND PREPARATION AND PURIFICATION PROCESS | July 2021 | October 2022 | Allow | 15 | 1 | 0 | Yes | No |
| 17370722 | GROUP VI PRECURSOR COMPOUNDS | July 2021 | September 2022 | Allow | 14 | 1 | 1 | Yes | No |
| 17370829 | Reagents and Methods for Esterification | July 2021 | September 2023 | Allow | 26 | 2 | 0 | No | No |
| 17366374 | SILYL-BIARYL PHOSPHORAMIDITES AND METHODS OF MAKING | July 2021 | July 2023 | Allow | 25 | 2 | 1 | No | No |
| 17363808 | PRODUCTION OF NITROGEN-CONTAINING CHELATORS | June 2021 | December 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17352382 | COMPOUNDS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | June 2021 | August 2023 | Abandon | 26 | 2 | 0 | No | No |
| 17351022 | SULFURIC ACID ESTER OR SALT THEREOF, AND SURFACTANT | June 2021 | April 2023 | Allow | 21 | 2 | 0 | No | No |
| 17312761 | LITHIUM ALKYL ALUMINATES AS ALKYL TRANSFER REAGENTS | June 2021 | January 2022 | Allow | 7 | 0 | 0 | Yes | No |
| 17340658 | MULTI-FUNCTIONALIZED HOLLOW FIBER ORGANOCATALYSTS | June 2021 | May 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17337065 | PROCESSES OF PREPARING A JAK1 INHIBITOR | June 2021 | February 2023 | Allow | 20 | 0 | 0 | No | No |
| 17336330 | COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | June 2021 | March 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17295316 | SELECTIVE DETECTION OF BED BUGS | May 2021 | July 2022 | Abandon | 14 | 1 | 0 | No | No |
| 17295222 | HIGH PURITY 2-NAPHTHYLACETONITRILE AND METHOD FOR PRODUCING SAME | May 2021 | December 2022 | Allow | 19 | 2 | 0 | No | No |
| 17314079 | ACETONITRILE PURIFICATION PROCESS FOR ULTRAHIGH PERFORMANCE LIQUID CHROMATOGRAPHY-MASS SPECTROMETER | May 2021 | December 2023 | Allow | 31 | 1 | 0 | No | No |
| 17239191 | HETEROCYCLIC COMPOUND AND USE THEREOF | April 2021 | March 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17237656 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | April 2021 | November 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 17284432 | PROTEIN KINASE INHIBITORS | April 2021 | December 2023 | Abandon | 32 | 2 | 1 | No | No |
| 17227071 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | April 2021 | May 2021 | Allow | 2 | 0 | 0 | No | No |
| 17281757 | METHOD FOR SYNTHESIZING AROMATIC SODIUM COMPOUND | March 2021 | November 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17218042 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | March 2021 | July 2021 | Allow | 3 | 0 | 0 | Yes | No |
| 17216285 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | March 2021 | November 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17280723 | CATALYZED AND GREEN PROCESS OF MALATHION | March 2021 | February 2022 | Allow | 11 | 0 | 0 | No | No |
| 17198987 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | March 2021 | March 2022 | Allow | 12 | 0 | 0 | No | No |
| 17190694 | HEXASUBSTITUTED BENZENES, SURFACES MODIFIED THEREWITH, AND ASSOCIATED METHODS | March 2021 | October 2021 | Allow | 8 | 0 | 0 | No | No |
| 17272765 | HYDROPHILIC METAL SURFACE TREATMENT AGENT | March 2021 | June 2021 | Allow | 3 | 0 | 0 | No | No |
| 17188063 | CRYSTALLINE FORMS OF ERAVACYCLINE | March 2021 | October 2022 | Allow | 19 | 1 | 0 | No | No |
| 17186820 | MACROCYCLIC INDOLE DERIVATIVES | February 2021 | March 2022 | Allow | 13 | 0 | 0 | No | No |
| 17185905 | Organic Electronic Device | February 2021 | February 2023 | Allow | 24 | 2 | 0 | No | No |
| 17271479 | HETEROCYCLIC COMPOUND | February 2021 | October 2023 | Allow | 32 | 0 | 0 | No | No |
| 17181776 | MATERIAL FOR FORMING ORGANIC FILM, SUBSTRATE FOR MANUFACTURING SEMICONDUCTOR DEVICE, METHOD FOR FORMING ORGANIC FILM, PATTERNING PROCESS, AND COMPOUND FOR FORMING ORGANIC FILM | February 2021 | September 2023 | Allow | 30 | 1 | 1 | No | No |
| 17248907 | JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE | February 2021 | May 2022 | Allow | 15 | 1 | 0 | No | No |
| 17171224 | METHOD FOR PREPARING 18F-BPA AND INTERMEDIATE | February 2021 | January 2023 | Allow | 23 | 1 | 1 | No | No |
| 17166662 | METHOD FOR PREPARING LEVETIRACETAM AND INTERMEDIATES THEREOF | February 2021 | February 2022 | Allow | 13 | 1 | 0 | No | No |
| 17161788 | PYRAZOLE DERIVATIVES | January 2021 | February 2023 | Allow | 24 | 2 | 1 | Yes | No |
| 17264333 | CRYSTALLINE FORMS OF A LTA4H INHIBITOR | January 2021 | March 2024 | Allow | 37 | 1 | 0 | No | No |
| 17156526 | PROCESS FOR THE PREPARATION OF HIGHLY PURE ERLOTINIB HYDROCHLORIDE | January 2021 | May 2024 | Abandon | 39 | 2 | 0 | No | No |
| 17262107 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS | January 2021 | October 2023 | Allow | 33 | 1 | 0 | No | No |
| 17153655 | CELL INTERNALIZING COMPOUNDS | January 2021 | December 2022 | Abandon | 23 | 1 | 1 | No | No |
| 17260226 | METHOD FOR PREPARING C-H ACIDIC (METH)ACRYLATES | January 2021 | October 2023 | Allow | 33 | 1 | 0 | No | No |
| 17248015 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | January 2021 | December 2021 | Allow | 11 | 0 | 0 | No | No |
| 17138578 | PROCESS FOR RECOVERING ADIPONITRILE | December 2020 | April 2024 | Abandon | 39 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KOSACK, JOSEPH R.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KOSACK, JOSEPH R works in Art Unit 1626 and has examined 1,190 patent applications in our dataset. With an allowance rate of 67.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.
Examiner KOSACK, JOSEPH R's allowance rate of 67.6% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KOSACK, JOSEPH R receive 1.44 office actions before reaching final disposition. This places the examiner in the 33% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KOSACK, JOSEPH R is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a -11.8% benefit to allowance rate for applications examined by KOSACK, JOSEPH R. This interview benefit is in the 1% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 28.9% of applications are subsequently allowed. This success rate is in the 44% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 53.4% of cases where such amendments are filed. This entry rate is in the 75% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 65.9% of appeals filed. This is in the 41% percentile among all examiners. Of these withdrawals, 69.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 77.9% are granted (fully or in part). This grant rate is in the 91% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.9% of allowed cases (in the 86% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 70% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.